The most expensive risk-sharing scheme that involved supplying multiple sclerosis (MS) medicines to patients, also known as the costliest publicly funding drug trail, has been termed as a failure by experts.

Charges are that the scheme wasted hundreds of millions of NHS money. This condemning has alerted authorities about the influence of pharmaceutical industry.

It has been sated that NHS could have saved £250 million if the scheme was accurately implemented after two good years.

Experts are saying that the wasted money should have been spent for much needed facilities that NHS required.

This deal started between the Government and drug firms after the National Institute for Health and Clinical Excellence said that the set of MS medicines was too expensive and also doubted the effectiveness of the drugs.

Currently also, similar schemes are functional for providing more drugs to NHS patients.

The scheme was finalized in 2002 when Government agreed to pay for the drugs. Meanwhile, research was conducted for the long-term cost effectiveness of the medicines.

According to the agreement, if the patients were not found to be benefitting by the drug use, NHS would gradually stop paying.

After seven long years of the execution of the scheme, in 2009, reports were published and it was concluded that “patients were performing less” than what was expected. But even after the evidences, it was said that pulling off the scheme and reducing prices without further analysis will be premature.

British Medical Journal (BMJ) cited Professor Christopher McCabe, a Health Economist at the University of Leeds and the lead expert, questioning the decision.